Journals / Experimed / 2023 / Cilt: 13 Sayı: 1

Large-Scale Proteomic Analysis of Patients with Type 2 Diabetes Mellitus and Atherosclerosis Using a Label-Free LC-MS/MS Approach

Journal
Experimed
Pages
26–38
Publication Date
2023-05-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that validation of these proteins with targeted proteomic approaches in a larger sample in further studies will contribute to the development of clinically usable panels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Type 2 diabetes mellitus (T2D) is a metabolic disease whose molecular events have not yet been fully clarified.
📊
Key Findings & Data:In this study, we aimed to reveal the protein profile of serum samples obtained from patients with T2D and atherosclerotic cardiovascular disease using the high-resolution liquid chromatography (LC)-MS/MS system.
💡
Conclusion & Impact:We believe that validation of these proteins with targeted proteomic approaches in a larger sample in further studies will contribute to the development of clinically usable panels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Diabetes · Proteomics · Serum

Abstract

Objective: Type 2 diabetes mellitus (T2D) is a metabolic disease whose molecular events have not yet been fully clarified. However, next-generation powerful molecular approaches such as mass spectrometry (MS)-based proteomics holds promise. In this study, we aimed to reveal the protein profile of serum samples obtained from patients with T2D and atherosclerotic cardiovascular disease using the high-resolution liquid chromatography (LC)-MS/MS system. Materials and Methods: Immune depletion was performed for the top 12 abundant proteins in 10 μl serum samples taken from individuals. Then, tryptic peptides were obtained from total proteins by applying a digestion protocol. Accordingly, reduction, alkylation, and digestion with trypsin enzyme were carried out, respectively. Tryptic peptides were analyzed in an ultra-high-pressure LC-MS/MS system with a label-free proteomic approach. The raw data were processed using the software program. Results: LC-MS/MS analyses revealed 120 proteins with significant expression changes. Some of these proteins were associated with inflammation, lipid transport, and oxidative stress, which are known to play an important role in T2D and its complications. Conclusion: As a result, LC-MS/MS analyses highlighted the proteins that will provide predictions in the treatment and course of T2D. We believe that validation of these proteins with targeted proteomic approaches in a larger sample in further studies will contribute to the development of clinically usable panels.

🔖

Cite This Article

SÜRMEN, M. G., BOZKAYA, T. A., ATEŞ, Ş., SÜRMEN, S., ÇAKICI, Ç., PENÇE, S., EMEKLİ, N. (2023). Large-Scale Proteomic Analysis of Patients with Type 2 Diabetes Mellitus and Atherosclerosis Using a Label-Free LC-MS/MS Approach. Experimed, Cilt: 13 Sayı: 1, 26–38. https://ajindex.com/articles/936352

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Isabel Padrao A, Ferreira R, Vitorino R, Amado F. Proteome-base biomarkers in diabetes mellitus: Progress on biofluids’ protein profiling using mass spectrometry. Proteomics Clin Appl 2012
  2. [CrossRef] google scholar 2. Shao S, Guo T, Aebersold R. Mass spectrometry-based proteomic quest for diabetes biomarkers. Biochim Biophys Acta 2015
  3. 1854(6): 519-27. [CrossRef] google scholar 3. Abdulwahab RA, Alaiya A, Shinwari Z, Allaith AAA, Giha HA. LC-MS/MS proteomic analysis revealed novel associations of 37 proteins with T2DM and notable upregulation of immunoglobulins. Int J Mol Med 2019
  4. 43(5): 2118-32. [CrossRef] google scholar 4. Lepedda AJ, Lobina O, Rocchiccioli S, Nieddu G, Ucciferri N, De Muro P, et al. Identification of differentially expressed plasma proteins in atherosclerotic patients with type 2 diabetes. J Diabetes Complications 2016
  5. 30(5): 880-6. [CrossRef] google scholar 5. Zhao L, Zhang Y, Liu F, Yang H, Zhong Y, Wang Y, et al. Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. J Endocrinol Invest 2021
  6. 44(12): 2709-23. [CrossRef] google scholar 6. Lee PY, Osman J, Low TY, Jamal R. Plasma/serum proteomics: depletion strategies for reducing high-abundance proteins for biomarker discovery. Bioanalysis 2019
  7. 11(19): 1799-1812. [CrossRef] google scholar 7. Ku EJ, Cho KC, Lim C, Kang JW, Oh JW, Choi YR, et al. Discovery of plasma biomarkers for predicting the severity of coronary artery atherosclerosis by quantitative proteomics. BMJ Open Diabetes Res Care 2020
  8. 8(1): e001152. [CrossRef] google scholar 8. Sürmen MG, Sürmen S, Cansız D, Ünal İ, Üstündağ ÜV, Alturfan AA, et al. Amelioration of rotenone-induced alterations in energy/ redox system, stress response and cytoskeleton proteins by octanoic acid in zebrafish: A proteomic study. J Biochem Mol Toxicol 2022
  9. 36(5): e23024. [CrossRef] google scholar 9. Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetesmellitus-related cardiovascular diseases. Curr Pharm Des 2013
  10. 19(32): 5695-703. [CrossRef] google scholar 10. Castro AR, Silva SO, Soares SC. The use of high sensitivity C-Reactive protein in cardiovascular disease detection. J Pharm Pharm Sci 2018
  11. 21(1): 496-503. [CrossRef] google scholar 11. Shimoda M, Kaneto H, Yoshioka H, Okauchi S, Hirukawa H, Kimura T, et al. Influence of atherosclerosis-related risk facto